Biosense Webster Granted FDA Approval for Multiple Atrial Fibrillation Ablation Products Designed for Fluoroscopy-Free Workflow

Saturday, August 05, 2023

Biosense Webster, a leading global company in cardiac arrhythmia treatment and a part of Johnson & Johnson MedTech, has announced that multiple products in its cardiac ablation portfolio have received approval from the U.S. Food and Drug Administration (FDA) for a zero fluoroscopy workflow. The approved products include the THERMOCOOL SMARTTOUCH™ SF catheter, which is widely used for RF ablation, as well as the THERMOCOOL SMARTTOUCH™ Catheter, CARTO® VIZIGO® Bi-Directional Guiding Sheath, PENTARAY® NAV ECO High-Density Mapping Catheter, DECANAV® Mapping Catheters, and Webster® CS Catheter.

The new workflow allows for direct imaging guidance, such as ultrasound, to be used as an alternative to fluoroscopy, which is a medical imaging technique involving continuous X-ray imaging on a monitor. This change is significant as fluoroscopy can expose patients to high radiation doses during complex interventional procedures, leading to potential long-term cancer risks and musculoskeletal pain from wearing heavy protective equipment like lead aprons.

The FDA-approved label change highlights the Biosense Webster integrated ecosystem's capabilities, anchored by the CARTO® 3 mapping and navigation system, and their diagnostic and treatment catheters, in enabling a workflow without the need for fluoroscopy. This advancement enhances the safety and efficiency of cardiac ablation procedures, benefitting both medical professionals and patients alike.



National Healthcare CMO Summit USANational Healthcare CNO Summit USA